GC Biopharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	49,372	22,563	49,706	105,366	186,060
Short-Term Investments	-0	0	0	-0	-
Trading Asset Securities	1,432	1,432	5,800	6,940	16,875
Cash & Short-Term Investments	50,804	23,995	55,506	112,306	202,935
Cash Growth	111.73%	-56.77%	-50.58%	-44.66%	-20.57%
Accounts Receivable	402,689	386,526	436,957	394,155	413,817
Other Receivables	2,408	9,635	11,976	13,778	9,624
Receivables	405,274	404,812	450,933	409,433	423,987
Inventory	891,582	746,582	516,245	442,408	454,976
Prepaid Expenses	11,724	9,638	4,147	4,157	3,275
Other Current Assets	10,862	16,806	12,316	12,133	5,346
Total Current Assets	1,370,247	1,201,833	1,039,148	980,437	1,090,519
Property, Plant & Equipment	960,461	915,826	952,703	930,822	899,847
Long-Term Investments	197,926	225,340	206,646	216,273	110,962
Goodwill	118,069	125,614	142,475	142,475	142,475
Other Intangible Assets	125,010	72,535	86,166	76,735	57,240
Long-Term Deferred Tax Assets	65,286	49,941	35,185	27,839	19,832
Long-Term Deferred Charges	94,214	109,236	109,240	92,353	77,691
Other Long-Term Assets	39,265	43,272	68,972	53,824	63,299
Total Assets	2,971,095	2,743,876	2,643,314	2,525,537	2,462,145
Accounts Payable	177,260	156,818	143,816	121,270	119,541
Accrued Expenses	71,168	54,140	34,000	102,066	85,781
Short-Term Debt	352,164	367,092	315,447	182,000	104,836
Current Portion of Long-Term Debt	256,584	10,829	202,813	5,416	120,539
Current Portion of Leases	14,799	14,304	14,335	11,580	9,887
Current Income Taxes Payable	9,251	7,873	2,041	17,158	28,338
Current Unearned Revenue	542	2,025	1,629	7,084	7,730
Other Current Liabilities	264,035	156,394	154,835	94,165	76,231
Total Current Liabilities	1,145,803	769,475	868,917	540,738	552,883
Long-Term Debt	253,501	339,506	84,891	278,797	280,343
Long-Term Leases	105,096	96,412	106,536	97,751	90,969
Long-Term Unearned Revenue	5,167	7,400	7,500	14,049	16,296
Pension & Post-Retirement Benefits	37,677	16,805	1,356	1,171	1,497
Long-Term Deferred Tax Liabilities	3,467	4,063	2,213	1,358	1,869
Other Long-Term Liabilities	26,111	29,200	32,038	25,031	18,531
Total Liabilities	1,576,822	1,262,860	1,103,451	958,895	962,388
Common Stock	58,433	58,433	58,433	58,433	58,433
Additional Paid-In Capital	396,224	396,220	393,605	393,531	385,821
Retained Earnings	796,529	815,336	872,989	903,467	867,353
Treasury Stock	-35,702	-35,702	-35,702	-35,702	-35,702
Comprehensive Income & Other	1,993	18,358	10,912	8,394	-1,134
Total Common Equity	1,217,477	1,252,645	1,300,236	1,328,122	1,274,771
Minority Interest	176,796	228,371	239,627	238,520	224,987
Shareholders' Equity	1,394,273	1,481,016	1,539,863	1,566,642	1,499,757
Total Liabilities & Equity	2,971,095	2,743,876	2,643,314	2,525,537	2,462,145
Total Debt	982,144	828,142	724,022	575,543	606,574
Net Cash (Debt)	-931,340	-804,147	-668,516	-463,238	-403,639
Net Cash Per Share	-81602.53	-70458.10	-58574.02	-40587.96	-35366.01
Filing Date Shares Outstanding	11.41	11.41	11.41	11.41	11.41
Total Common Shares Outstanding	11.41	11.41	11.41	11.41	11.41
Working Capital	224,444	432,358	170,231	439,698	537,637
Book Value Per Share	106673.41	109754.26	113924.12	116367.45	111692.86
Tangible Book Value	974,398	1,054,496	1,071,595	1,108,912	1,075,056
Tangible Book Value Per Share	85375.23	92392.82	93891.05	97160.69	94194.24
Land	17,524	17,509	17,346	17,383	18,025
Buildings	714,516	705,071	695,794	638,353	572,756
Machinery	453,357	430,546	407,055	369,503	333,326
Construction In Progress	70,947	43,028	59,224	103,334	150,176

Source: S&P Global Market Intelligence. Standard template. Financial Sources.